아시아태평양의 세포 및 유전자 치료 제조 QC 시장 : 분석과 예측(2024-2033년)

Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2024-2033

US $ 3,250 ￦ 4,702,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,900 ￦ 7,089,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아시아태평양의 세포 및 유전자 치료 제조 QC 시장 규모는 2023년 2억 4,640만 달러에 달했습니다.

이 시장은 2024-2033년 예측 기간 동안 18.36%의 CAGR로 성장하여 2033년까지 13억 1,730만 달러에 달할 것으로 예상됩니다. 이 시장은 CAR T 세포와 같은 혁신적인 치료법의 채택 확대가 주요 요인으로 작용하여 두 자릿수 성장세를 보이고 있습니다. 세포와 유전자를 이용한 치료의 안전성, 유효성, 일관성을 보장하기 위해서는 탄탄한 품질 관리 프로세스가 필수적입니다. 이 시장은 제조 과정에서 엄격한 품질 관리 조치의 필요성, 제조 기술의 발전, 규제 프레임워크의 확대에 의해 주도되고 있습니다. 시장 기회를 활용하기 위해 업계 기업들은 혁신적인 QC 기술 개발, 강력한 분석법 확립, 규제 기관 및 학술 기관과의 협력에 주력하고 있습니다. 규제 요건을 충족하고 이 역동적이고 변화무쌍한 시장에서 성공하기 위해서는 제조업체가 종합적인 QC 전략을 실행하는 것이 매우 중요합니다.

주요 시장 통계
예측 기간	2024-2033년
2024년 평가	2억 8,890만 달러
2033년 예측	13억 1,730만 달러
CAGR	18.36%

아시아태평양의 세포 및 유전자 치료제 제조 QC 시장은 암, 대사성 질환, 자가면역질환 등 대상 질환의 유병률 증가에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 또한, 세포 및 유전자 치료제의 승인이 증가하고 있는 것도 시장 확대에 기여하고 있습니다. 또한, 세포 및 유전자 치료 분야에 대한 신규 진입과 투자가 지속적으로 증가하고 있으며, 이는 아시아태평양의 세포 및 유전자 치료 제조 QC 시장을 강화하여 이러한 치료법 제조에 필요한 제품, 서비스 및 솔루션에 대한 수요가 급증하고 있습니다.

Danaher Corporation(Cytiva), F. Hoffmann-La Roche Ltd, THERMO FISHER SCIENTIFIC INC. 등의 주요 기업이 주도하는 아시아태평양의 세포 및 유전자 치료제 제조 QC 시장은 세포 및 유전자 치료제 제조의 전망을 바꾸어 놓았습니다. 변화시켰습니다. 이들 업계 리더들은 세포 및 유전자 치료제 제조의 안전성, 유효성 및 규정 준수라는 복잡한 과제를 해결하기 위해 혁신적인 QC 솔루션을 도입하고 있습니다.

R&D 투자와 임상시험의 증가에 힘입어 바이오의약품 혁신이 빠르게 성장함에 따라 이 지역에서는 고급 QC 메커니즘에 대한 수요가 증가하고 있습니다. 자동화, 실시간 모니터링, 통합 분석은 워크플로우를 간소화하고 비용을 절감하며, 이들 기업의 기술은 효율성의 새로운 벤치마크가 되고 있습니다.

아시아태평양의 세포 및 유전자 치료제 제조 QC 시장에 대해 조사했으며, 시장 개요, 제품별, 치료 유형별, 공정별, 기술별, 용도별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장

제2장 세포 및 유전자 치료 제조 QC 시장 : 규제 프레임워크

• 식품 의약품국(FDA)에 의한 화학, 제조, 관리(CMC) 요건
• 유럽 의약품청(EMA)에 의한 세포 및 유전자 치료 제품 품질 측면
• 현행 적정 제조 규범(CGMP) 규제
• 세계 규제 프레임워크 : 세포 및 유전자 치료 제조 QC 시장

제3장 아시아태평양의 세포 및 유전자 치료 제조 QC 시장 : 시장 개요

• 시장 개요
• 시장 발자국과 성장의 가능성
• 향후의 가능성
• COVID-19의 시장에 대한 영향
• 시장 역학
• 시장 규모와 예측
  • 아시아태평양의 세포 및 유전자 치료 제조 QC 시장(제공별)
  • 아시아태평양의 세포 및 유전자 치료 제조 QC 시장(치료 유형별)
  • 아시아태평양의 세포 및 유전자 치료 제조 QC 시장(프로세스별)
  • 아시아태평양의 세포 및 유전자 치료 제조 QC 시장(기술별)
  • 아시아태평양의 세포 및 유전자 치료 제조 QC 시장(용도별)

제4장 아시아태평양의 세포 및 유전자 치료 제조 QC 시장 : 국가별

• 싱가포르
• 일본
• 한국
• 호주
• 인도
• 태국
• 말레이시아
• 인도네시아
• 기타

제5장 기업 개요

• Bio-Techne Corporation
• Danaher Corporation(Cytiva)
• F. Hoffmann-La Roche Ltd
• Lonza
• Miltenyi Biotec B.V. & Co. KG
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi AppTec
• Fujifilm Holdings Corporation
• Merck KGaA

ksm

영문 목차

영문목차

An Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC

The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $246.4 million in 2023 and is anticipated to reach $1,317.3 million by 2033, witnessing a CAGR of 18.36% during the forecast period 2024-2033. The given figure illustrates the market revenue of the Asia-Pacific cell and gene therapy manufacturing QC market from 2023-2033. The market has been witnessing impressive double-digit growth, largely driven by the increasing adoption of innovative therapies such as CAR T-cells and others. Robust quality control processes are essential to ensure cell and gene-based treatments' safety, efficacy, and consistency. The market is driven by the need for stringent QC measures throughout the manufacturing journey, advancements in manufacturing technologies, and expanding regulatory frameworks. To capitalize on market opportunities, industry players are focusing on developing innovative QC technologies, establishing robust analytical methods, and collaborating with regulatory bodies and academic institutions. It is crucial for manufacturers to implement comprehensive QC strategies to meet regulatory requirements and position themselves for success in this dynamic and transformative market.

Market Introduction

KEY MARKET STATISTICS
Forecast Period	2024 - 2033
2024 Evaluation	$288.9 Million
2033 Forecast	$1,317.3 Million
CAGR	18.36%

The Asia-Pacific cell and gene therapy manufacturing QC market has been experiencing notable growth, driven by the escalating prevalence of target diseases such as cancers, metabolic disorders, autoimmune disorders, and others. Additionally, the increasing approval of cell and gene therapies has further contributed to this market expansion. Furthermore, there has been a consistent rise in the number of new entrants and investments in the field of cell and gene therapy, which has strengthened the Asia-Pacific cell and gene therapy manufacturing QC market, thereby providing a surge in demand for the products and services solutions required in the manufacturing of these therapies. For instance, as per an article titled 'Cell & Gene Therapy in the Asia Pacific: Revolutionizing Disease Treatment,' published in 2023, South Korea has established a $1.3 billion fund to support the development of cell and gene therapies. Further, Singapore has invested in several initiatives to support the development of cell and gene therapies, including the establishment of the Singapore Consortium for Synthetic Biology and the Bioprocessing Technology Institute. Therefore, the impact of the aforementioned factors is expected to drive the Asia-Pacific cell and gene therapy manufacturing QC market in the forecast period 2024-2033.

Industrial Impact

The Asia-Pacific cell and gene therapy manufacturing QC market, driven by leading companies such as Danaher Corporation (Cytiva), F. Hoffmann-La Roche Ltd, and THERMO FISHER SCIENTIFIC INC., has transformed the landscape of cell and gene therapy manufacturing. These industry leaders have introduced innovative QC solutions to address the complexities of ensuring safety, efficacy, and compliance in cell and gene therapy production.

The region's rapid growth in biopharmaceutical innovation, supported by increased R&D investments and clinical trials, has created a robust demand for advanced QC mechanisms. Automation, real-time monitoring, and integrated analytics have streamlined workflows and reduced costs, with technologies from these companies setting new benchmarks for efficiency.

The region's stringent regulatory environment and expanding manufacturing capacities further drive the adoption of scalable and precise QC technologies. With a focus on tailored solutions for diverse regional needs, these advancements are accelerating time-to-market for therapies, enhancing product integrity, and reinforcing regulatory compliance. As the market evolves, trends such as AI-driven predictive analytics and real-time release testing will continue to shape its trajectory in cell and gene therapy manufacturing.

Market Segmentation:

Segmentation 1: by Offering

• Products
• Services

Services Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC market (by Offering)

Based on offering, the Asia-Pacific cell and gene therapy manufacturing QC market was led by the services segment, which held a 70.28% share in 2023. The high growth of the services segment can be attributed to the increase in outsourcing manufacturing and QC operations to CDMOs and CROs.

Segmentation 2: by Therapy Type

• Cell Therapy
• Gene Therapy

Cell Therapy Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)

Based on therapy type, the cell therapy segment accounted for the largest share of 58.42% in the Asia-Pacific cell and gene therapy manufacturing QC market in 2023. In addition, cell therapy is expected to witness the highest growth rate of 19.47% in the forecast period 2024-2033. The growth of the cell therapy segment can be attributed to the ongoing advancements and increasing regulatory approvals for CAR-T cell therapies.

Segmentation 3: by Process

• Raw Materials Preparation
• Upstream Processing
• Downstream Processing
• Packaging

Upstream Processing Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)

Based on process, the upstream processing segment accounted for the largest share of 47.10% in the Asia-Pacific cell and gene therapy manufacturing QC market in 2023. Moreover, upstream processing is expected to hold the highest growth rate of 19.45% in the forecast period 2024-2033. This can be attributed to the shift toward the usage of single-use bioreactors for cell and gene therapy manufacturing, as these systems reduce contamination risks and allow for streamlined QC protocols.

Segmentation 4: by Technology

• Polymerase Chain Reaction
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing
• Electrophoresis
• Other Technologies

PCR Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)

Based on technology, the PCR segment accounted for the largest share of 23.98% in the Asia-Pacific cell and gene therapy manufacturing QC market in 2023. However, the next-generation sequencing segment is expected to hold the highest growth rate of 22.68% in the forecast period 2024-2033. The high growth of the next-generation sequencing segment can be attributed to the ability of NGS to provide detailed genetic profiles with high sensitivity, allowing for a thorough assessment of cell lines, vector purity, off-target effects in gene editing, and genetic modifications.

Segmentation 5: by Application

• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others

Safety Testing Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

Based on application, the safety testing segment accounted for the largest share of 46.15% in the Asia-Pacific cell and gene therapy manufacturing QC market in 2023. However, the potency testing segment is expected to hold the highest growth rate of 20.28% in the forecast period 2024-2033. The high growth rate of the potency testing segment can be attributed to the continuous developments in potency assays and their essential role in efficacy validation.

Recent Developments in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

• In January 2023, Bio-Techne Corporation announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio. It launched an RNAscope Plus smRNA-RNA detection assay that enables simultaneous fluorescence detection of small regulatory RNA together with three target RNAs or RNA biomarkers in the same tissue section at single-cell and subcellular resolution.
• In August 2023, Cytiva collaborated with Genepeutic Bio to establish Thailand's first GMP-certified cell therapy manufacturing facility. The collaboration is expected to boost the capabilities of cancer treatment delivery within Thailand and Southeast Asia.
• In April 2023, Cytiva launched X-platform bioreactors, which aim to streamline single-use upstream bioprocessing operations. These versatile bioreactors can be used for producing monoclonal antibodies, protein-based drugs, cell and gene therapies, and viral vectors. They offer flexibility and efficiency in bioprocessing, facilitating the development and manufacturing of various therapeutic products.
• In February 2023, AcuraBio, a contract development and manufacturing organization (CDMO), is expanding its current good manufacturing practice (cGMP) plasmid DNA services using Cytiva's single-use purification technology. This expansion is aimed at addressing supply constraints for mRNA and cell and gene therapies.
• In July 2022, Forecyte Bio collaborated with Cytiva to expedite the development and manufacturing of cell and gene therapies. This collaboration aimed to standardize processes within the CGT CDMO sector and drive industry growth.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Increasing Number of Approvals Leading to an Upsurge in Demand for Cell and Gene Therapies QC Testing: The increasing number of regulatory approvals for cell and gene therapies is driving a significant upsurge in demand for quality control (QC) testing in the Asia-Pacific region. As innovative therapies move from clinical trials to commercial availability, ensuring their safety, efficacy, and consistency becomes paramount. Regulatory bodies across major markets such as Japan, Australia, and South Korea have established stringent approval processes, emphasizing robust QC measures. This has necessitated the adoption of advanced testing technologies capable of addressing the complexities of cell and gene therapies, including sterility, potency, identity, and safety evaluations. Key industry players have been responding to this demand by developing automated and scalable QC solutions, enabling faster and more reliable testing workflows. With the rapid expansion of manufacturing capacities and growing patient access to these therapies, the role of QC testing in maintaining compliance and ensuring product quality continues to grow, marking it as a critical factor in the industry's ongoing evolution.

Market Challenges:

Limited Adoption of Cell and Gene Therapy Due to High Manufacturing and QC Costs: The adoption of cell and gene therapies in the Asia-Pacific region is currently limited by the high costs associated with manufacturing and quality control (QC). These therapies involve complex processes, including cell isolation, genetic modification, and precision delivery, which demand highly specialized equipment, skilled personnel, and stringent QC measures. QC testing, in particular, requires advanced technologies to ensure these therapies' safety, efficacy, and consistency, driving up operational costs. This financial burden is further compounded by the lack of standardized manufacturing protocols and economies of scale, as cell and gene therapies are often produced in small batches tailored to individual patients or specific conditions.

Small and medium-sized biopharmaceutical companies face significant challenges in overcoming these cost barriers, which can delay the scaling of innovative treatments. Additionally, the need for comprehensive compliance with stringent regulatory requirements adds to the financial and operational strain. To address these challenges, industry players and governments are increasingly investing in automation, process optimization, and scalable QC solutions to reduce costs. Partnerships and collaborations among stakeholders also aim to share resources and expertise, paving the way for broader adoption and access to these life-saving therapies. However, overcoming these cost-related barriers remains a critical hurdle for the region's widespread implementation of cell and gene therapies.

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific cell and gene therapy manufacturing QC market has been extensively segmented based on offering, therapy type, process, technology, and application. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific cell and gene therapy manufacturing QC market has numerous established players with significant product portfolios. Key players in the Asia-Pacific cell and gene therapy manufacturing QC market analyzed and profiled in the study involve established players offering products and services for cell and gene therapy.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2033.
• The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of products and services of the Asia-Pacific cell and gene therapy manufacturing QC market.
• The market contribution of Asia-Pacific cell and gene therapy manufacturing QC is anticipated to be launched and calculated based on the historical analysis of the solutions.
• The company's revenue has been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
• The market has been mapped based on the available cell and gene therapy manufacturing QC in the Asia-Pacific. This report has considered and profiled all the key companies with significant offerings in this field.

Primary Research:

The primary sources involve industry experts in cell and gene therapy manufacturing QC, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding the competitive landscape and business model
• Current and proposed production values of a product by market players
• Validation of the numbers of the different segments of the market in focus
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• Segmentations and percentage shares
• Data for market value
• Key industry trends of the top players of the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Bio-Techne Corporation
• Danaher Corporation (Cytiva)
• F. Hoffmann-La Roche Ltd
• Lonza
• Miltenyi Biotec B.V. & Co. KG
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi AppTec
• Fujifilm Holdings Corporation
• Merck KGaA

Table of Contents

1 Markets

• 1.1 Product Definition
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
• 1.2 Market Scope
  • 1.2.1 Scope of the Work
  • 1.2.2 Key Questions Answered in the Report
• 1.3 Research Methodology
  • 1.3.1 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 1.3.2 Data Sources
    • 1.3.2.1 Primary Data Sources
    • 1.3.2.2 Secondary Data Sources
  • 1.3.3 Market Estimation Model

2 Cell and Gene Therapy Manufacturing QC Market: Regulatory Framework

• 2.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
  • 2.1.1 Product Testing
  • 2.1.2 Microbial Testing
  • 2.1.3 Identity
  • 2.1.4 Purity
  • 2.1.5 Potency
  • 2.1.6 Viability
  • 2.1.7 Cell Number or Dose
• 2.2 Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
  • 2.2.1 Characterization
  • 2.2.2 Identity Testing
  • 2.2.3 Purity Testing
• 2.3 Current Good Manufacturing Practice (CGMP) Regulations
  • 2.3.1 U.S.
  • 2.3.2 Europe
  • 2.3.3 Asia-Pacific
• 2.4 Global Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Market Overview

• 3.1 Market Overview
  • 3.1.1 Realistic Growth Scenario
  • 3.1.2 Optimistic Scenario
  • 3.1.3 Pessimistic Scenario
• 3.2 Market Footprint and Growth Potential
• 3.3 Future Potential
• 3.4 COVID-19 Impact on Market
  • 3.4.1 Impact on Research and Clinical Operations
  • 3.4.2 COVID-19 Impact: Current Scenario of the Market
  • 3.4.3 Pre- and Post-COVID-19 Impact Assessment
    • 3.4.3.1 Pre-COVID-19 Phase
    • 3.4.3.2 Post-COVID-19 Phase
• 3.5 Market Dynamics
• 3.6 Market Sizing and Forecast
  • 3.6.1 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 3.6.2 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 3.6.3 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 3.6.4 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 3.6.5 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

4 Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: by Country

• 4.1 Singapore
  • 4.1.1 Singapore Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.1.2 Singapore Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.1.3 Singapore Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.1.4 Singapore Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.1.5 Singapore Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.2 Japan
  • 4.2.1 Japan Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.2.2 Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.2.3 Japan Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.2.4 Japan Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.2.5 Japan Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.3 South Korea
  • 4.3.1 South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.3.2 South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.3.3 South Korea Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.3.4 South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.3.5 South Korea Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.4 Australia
  • 4.4.1 Australia Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.4.2 Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.4.3 Australia Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.4.4 Australia Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.4.5 Australia Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.5 India
  • 4.5.1 India Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.5.2 India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.5.3 India Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.5.4 India Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.5.5 India Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.6 Thailand
  • 4.6.1 Thailand Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.6.2 Thailand Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.6.3 Thailand Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.6.4 Thailand Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.6.5 Thailand Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.7 Malaysia
  • 4.7.1 Malaysia Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.7.2 Malaysia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.7.3 Malaysia Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.7.4 Malaysia Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.7.5 Malaysia Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.8 Indonesia
  • 4.8.1 Indonesia Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.8.2 Indonesia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.8.3 Indonesia Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.8.4 Indonesia Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.8.5 Indonesia Cell and Gene Therapy Manufacturing QC Market (by Application)
• 4.9 Rest-of-Asia-Pacific
  • 4.9.1 Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
  • 4.9.2 Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
  • 4.9.3 Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
  • 4.9.4 Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
  • 4.9.5 Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

5 Company Profiles

• 5.1 Bio-Techne Corporation
  • 5.1.1 Company Overview
  • 5.1.2 Role of Bio-Techne Corporation in the Cell and Gene Therapy Manufacturing QC Market
  • 5.1.3 Product Portfolio
  • 5.1.4 Key Competitors
  • 5.1.5 Financials
  • 5.1.6 Analyst Perspective
• 5.2 Danaher Corporation (Cytiva)
  • 5.2.1 Company Overview
  • 5.2.2 Role of Danaher Corporation (Cytiva) in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.2.3 Product Portfolio
  • 5.2.4 Key Competitors
  • 5.2.5 Financials
  • 5.2.6 Analyst Perspective
• 5.3 F. Hoffmann-La Roche Ltd
  • 5.3.1 Company Overview
  • 5.3.2 Role of F. Hoffmann-La Roche Ltd in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.3.3 Product Portfolio
  • 5.3.4 Key Competitors
  • 5.3.5 Financials
  • 5.3.6 Analyst Perspective
• 5.4 Lonza
  • 5.4.1 Company Overview
  • 5.4.2 Role of Lonza in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.4.3 Product Portfolio
  • 5.4.4 Key Competitors
  • 5.4.5 Financials
  • 5.4.6 Analyst Perspective
• 5.5 Miltenyi Biotec B.V. & Co. KG
  • 5.5.1 Company Overview
  • 5.5.2 Role of Miltenyi Biotec B.V. & Co. KG in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.5.3 Product Portfolio
  • 5.5.4 Key Competitors
  • 5.5.5 Analyst Perspective
• 5.6 Sartorius AG
  • 5.6.1 Company Overview
  • 5.6.2 Role of Sartorius AG in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.6.3 Product Portfolio
  • 5.6.4 Key Competitors
  • 5.6.5 Financials
  • 5.6.6 Analyst Perspective
• 5.7 Thermo Fisher Scientific Inc.
  • 5.7.1 Company Overview
  • 5.7.2 Role of Thermo Fisher Scientific Inc. in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.7.3 Product Portfolio
  • 5.7.4 Key Competitors
  • 5.7.5 Financials
  • 5.7.6 Analyst Perspective
• 5.8 WuXi AppTec
  • 5.8.1 Company Overview
  • 5.8.2 Role of WuXi AppTec in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.8.3 Product Portfolio
  • 5.8.4 Key Competitors
  • 5.8.5 Financials
  • 5.8.6 Analyst Perspective
• 5.9 Fujifilm Holdings Corporation
  • 5.9.1 Company Overview
  • 5.9.2 Role of Fujifilm Holdings Corporation in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.9.3 Product Portfolio
  • 5.9.4 Key Competitors
  • 5.9.5 Financials
  • 5.9.6 Analyst Perspective
• 5.10 Merck KGaA
  • 5.10.1 Company Overview
  • 5.10.2 Role of Merck KGaA in the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market
  • 5.10.3 Product Portfolio
  • 5.10.4 Key Competitors
  • 5.10.5 Financials
  • 5.10.6 Analyst Perspective

List of Tables

• Table 1: Summary of Regulatory Requirements in Asia-Pacific
• Table 2: Key Questions Answered in the Report
• Table 3: Global Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
• Table 4: List of Approved CGT Drugs in Asian Countries
• Table 5: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis
• Table 6: Some of the Approved Cell and Gene Therapies in Japan

관련자료